Astellas Pharma and CV Therapeutics have obtained FDA approval for their heart-imaging agent regadenoson. The drug, also known as Lexiscan, was cleared for use during cardiac stress tests in patients not fit enough to undergo traditional exercise tests on a treadmill, the drugmakers said.

Full Story:
Bloomberg, Reuters

Related Summaries